Provention Bio Inc.

NASDAQ: PRVBHealthcare / Biotechnology / USA
10.45+1.20+12.97%Vol 318 0031Y Perf 172.85%
Aug 21st, 2019 16:00
BID10.45 ASK10.49
Open9.31 Previous Close9.25
Pre-Market- After-Trading-
 - -%  - -%
Target Price
25.00 
Analyst Rating
Strong Buy 1.00
Potencial %
139.23 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
75/75/92 
Value Ranking
 —    -
Insiders Value % 3/6/12M
80/80/85 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
82/82/93 
Income Ranking
 —    -
Market Cap (mil)411 
Earnings Rating
Sell
Price Range Ratio 52wk %
41.92 
Earnings Date
12th Aug 2019

Today's Price Range

9.2410.49

52wk Range

1.5222.82

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
12.24%
1 Month
-7.93%
3 Months
175.00%
6 Months
331.82%
1 Year
172.85%
3 Years
-
5 Years
-
10 Years
-

Name / TickerPriceChg.Chg.%
PRVB10.451.200012.97
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.31-0.32-3.23
Q01 2019-0.19-0.29-52.63
Q04 2018-0.19-0.1521.05
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.32-6.67Negative
12/2019 QR-0.3165.17Positive
12/2019 FY-1.21-9.01Negative
12/2020 FY-1.19-26.60Negative
Next Report Date-
Estimated EPS Next Report-0.31
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume318 003
Shares Outstanding (in ths.)39 337
Trades Count1 427
Dollar Volume3 134 187
Avg. Volume419 445
Avg. Weekly Volume295 762
Avg. Monthly Volume442 831
Avg. Quarterly Volume982 563
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Provention Bio Inc.

Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in the sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. The company's pipeline includes PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-101.

CEO: Ashleigh Palmer

Teplephone: +1 908 336-0360

Address: P.O. Box 666, Oldwick 08858, NJ, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

31%69%

Bearish Bullish

50%50%

News